Anonymous
Guest
Anonymous
Guest
I am considering interviewing with Octapharma, and as usual this board seems to be mostly disgruntled pharma/bio reps adjusting to the new age of healthcare sales in which one actually has to ask for the business and negotiate to close.
That being said, my intent is not to offend anyone who has a legitimate gripe related to something other that the usual day to day grind and treatment in the corporate world.
I'm not looking for specifics related to salary, cars, etc. as that comes with seasoned negotiating skills and is different for everyone. I would like to know if Octapharma is a viable player in the IVIG market and, possibly more importantly, is IVIG viable therapy in the minds of the medical population. What is the most promising therapeutic frontier MS, Infertility? Are competitive products truly differentiated in any way other than type and level of sugar? At roughly $3,000 per infusion plus monthly maintenance is there enough margin in this therapy for a proven performer to be well compensated?
I'm sure I will receive the usual percentage of humorous (and not so) responses. Thanks for some of those and greater thanks to anyone who is involved in a succesful future with Octapharma and takes the time to respond.
That being said, my intent is not to offend anyone who has a legitimate gripe related to something other that the usual day to day grind and treatment in the corporate world.
I'm not looking for specifics related to salary, cars, etc. as that comes with seasoned negotiating skills and is different for everyone. I would like to know if Octapharma is a viable player in the IVIG market and, possibly more importantly, is IVIG viable therapy in the minds of the medical population. What is the most promising therapeutic frontier MS, Infertility? Are competitive products truly differentiated in any way other than type and level of sugar? At roughly $3,000 per infusion plus monthly maintenance is there enough margin in this therapy for a proven performer to be well compensated?
I'm sure I will receive the usual percentage of humorous (and not so) responses. Thanks for some of those and greater thanks to anyone who is involved in a succesful future with Octapharma and takes the time to respond.